Skip to main content

Novel Rx

EMA/European Commission has aproved Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults https://t.co/Fv9DON1AvB https://t.co/Li79tKzMxK
Dr. John Cush @RheumNow( View Tweet )

Breaking the Rules: Dual-Advanced Combinations in Rheumatology

For decades, the standard of care in rheumatology has been combination therapy - pairing methotrexate (MTX) with an advanced biologic or synthetic agent to achieve optimal outcomes. 

Read Article
DERM on RheumNow PODCAST (April 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy and side https://t.co/SlCGA364gj
Dr. John Cush @RheumNow( View Tweet )
Anifrolumab (Saphnelo) approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus based on SC-TULIP study. Presumeably, all prior CRL issues resolved to FDA satisfaction... https://t.co/ZtZmJLcGYa https://t.co/4B2YDpFaep
Dr. John Cush @RheumNow( View Tweet )

Great Lectures; Great Presentations

Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

Read Article
APR: Methotrexate Companion slide deck for the Advanced Practice Rheum: Methotrexate video, featuring Dr. Jack Cush. https://t.co/8422FKN4dq https://t.co/6gVS7dA8Gi
Dr. John Cush @RheumNow( View Tweet )
FDA has accepted Genetech application for obinutuzumab (Gazyva) to treat SLE (currently only approved for lupus nephritis) - based on Phase III ALLEGORY study w/ Gazyva showing signif reduced dz activity https://t.co/louTYyN6bN https://t.co/Hy1gGliamn
Dr. John Cush @RheumNow( View Tweet )
TriNetX study of 7,929 RA pts Rx w/ bDMARDs (n 2668) w/in 6 mos of elective hand surgery - perioperative bDMARD continuation (34%) was not associated with significant increases in risks of wound healing failures (1.4% vs 1.4%) or SSI (2% vs 1.5%) https://t.co/NY6l2jRswb https://t.co/IxoYtLNGvf
Dr. John Cush @RheumNow( View Tweet )

Follow the Money (4.23.2026)

Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week. 

Read Article
Weight-loss drugs may affect joints directly A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis. https://t.co/xKm8Ng7fXO
Dr. John Cush @RheumNow( View Tweet )

Weight-loss drugs may affect joints directly

EulrekAlert!

A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis.

Rsearchers from the Department of Biomedicine at Aarhus

Read Article
Malignancies Not Increased with Biologic Therapies The risk of malignancy in RA patients receiving biologic agents was evaluated by metanalysis of RCTs and found no significant increased risk of malignancy compared with other DMARDs or with placebo. https://t.co/ZEO4jP5RwA https://t.co/C1YeTSh7ZN
Dr. John Cush @RheumNow( View Tweet )

Prescribing Lessons (4.17.2026)

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
152 pts w/ immune thrombocytopenia (ITP) Rx in DBRPCT of Ianalumab (9mg or 3 mg/kg) or PBO q mo x 4 mos (all on Eltrombopag). Time to Rx failure signif longer w/ ianalumab. Stable 6 month response better w/ 9-mg group vs PBO (62% vs 39%; P=0.045) https://t.co/J04trYAwLu https://t.co/Alm8V2SAXn
Dr. John Cush @RheumNow( View Tweet )
Litifilimab in Cutaneous Lupus Erythematosus Biogen has announced positive results of their Phase 2 study, evaluating litifilimab in patients with active cutaneous lupus erythematosus (CLE), presented at the recent American Academy of Dermatology (AAD) Annual Meeting. https://t.co/3Wb6iFViOm
Dr. John Cush @RheumNow( View Tweet )

Still's Disease Update

Arthritis Research & Therapy has published an overarching review of Still's disease - claiming it to be a single acquired and complex autoinflammatory disease in which both pediatric and adult forms share core pathogenic mechanisms, genetic associations and clinical presentations, with minor

Read Article

Litifilimab in Cutaneous Lupus Erythematosus

Biogen has announced positive results of their Phase 2 study, evaluating litifilimab in patients with active cutaneous lupus erythematosus (CLE), presented at the recent American Academy of Dermatology (AAD) Annual Meeting.

Litifilimab is an investigational monoclonal antibody that

Read Article

Modest Benefits with AI Scribes on EHR Documentation

EurekAlert!

Documenting a patient visit in the electronic health record (EHR) is essential to healthcare delivery, but also a major contributor to clinician burnout. Artificial intelligence (AI)-enabled ambient documentation, or “AI scribes,” can automatically generate draft clinical notes for review

Read Article
OL phase 2 study 50 active systemic JIA pts Randomized to IL-1 inhibitor, firsekibart or TCZ q2wk x 24 wks. At day 28, modified ACR Pedi 30response (no fever) favored FIRS 3mg dose (94% vs 75% vs 82%). Also higher ACR Pedi 70/90 responses & steriod tapers. https://t.co/8bdCLUFFLT https://t.co/ddQe7k25UE
Dr. John Cush @RheumNow( View Tweet )
Couldn’t attend https://t.co/4UQlqwujiR 2026? You can now watch the entire meeting On Demand. This high-impact program features leading experts discussing: • RA outcomes and pathogenesis • Obesity, inflammation, and rheumatic disease • Treatment decisions in Psoriatic https://t.co/A3wb3pzbl3
Dr. John Cush @RheumNow( View Tweet )

Malignancies Not Increased with Biologic Therapies

The risk of malignancy in rheumatoid arthritis (RA) patients receiving biologic agents was evaluated by metanalysis of randomized controlled trials (RCTs) and found no significant increased risk of malignancy compared with other disease-modifying antirheumatic drugs (DMARDs) or with placebo

Read Article

JAMA Guideline on the Management of Crohn Disease

JAMA has published a current Clinical Guidelines Synopsis on the Management of Crohn Disease (CD) in Adults.

Read Article
Brepocitinib in Dermatomyositis The NEJM reports that brepocitinib, an oral TYK2–JAK1 inhibitor, was studied in a phase 3 trial of refractory dermatomyositis (DM) patients and shown to have significant benefits at the higher dose. https://t.co/gYLP5artRZ https://t.co/PHYXEzzM2j
Dr. John Cush @RheumNow( View Tweet )
AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N

Dr. John Cush @RheumNow( View Tweet )

Brepocitinib in Dermatomyositis The NEJM reports that brepocitinib, an oral TYK2–JAK1 inhibitor, was studied in a phase 3 trial of refractory dermatomyositis (DM) patients and shown to have significant benefits at the higher dose. https://t.co/YNxrVTIubb https://t.co/uFY3kMOvui
Dr. John Cush @RheumNow( View Tweet )
×